EGFR Mutation Positive Stage IV Non-Small-Cell Lung Cancer: Treatment Beyond Progression (original) (raw)

Journal of thoracic disease, 2016

Efficacy and safety of epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) monotherapy for advanced EGFR-mutated non-small cell lung cancer: systematic review and meta-analysis

Elena Dragioti

DOAJ (DOAJ: Directory of Open Access Journals), 2021

View PDFchevron_right

Distinct Clinical Outcomes of Non-Small Cell Lung Cancer Patients with Epidermal Growth Factor Receptor (EGFR) Mutations Treated with EGFR Tyrosine Kinase Inhibitors: Non-Responders versus Responders

Chi-li Chung

PLoS ONE, 2013

View PDFchevron_right

Clinical outcomes in non-small-cell lung cancer patients with EGFR mutations: pooled analysis

Luis Paz-ares

Journal of Cellular and Molecular Medicine, 2010

View PDFchevron_right

Navigating the "No Man's Land" of TKI-Failed EGFR-Mutated Non-Small Cell Lung Cancer (NSCLC): A Review

Corey Carter

Neoplasia (New York, N.Y.), 2018

View PDFchevron_right

Intercalated chemotherapy and erlotinib for non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) mutations

Mirjana Rajer

Cancer Biology & Therapy, 2016

View PDFchevron_right

Does the efficacy of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor differ according to the type of EGFR mutation in non-small cell lung cancer?

Jin-Hyuk Choi

The Korean journal of internal medicine, 2017

View PDFchevron_right

Real world impact of epidermal growth factor receptor mutation status on treatment patterns in patients with non-small cell lung cancer

S. Rampal

Lung Cancer, 2013

View PDFchevron_right

Overall Survival Analysis and Characterization of an EGFR Mutated Non-Small Cell Lung Cancer (NSCLC) Population

Venceslau Hespanhol

Archivos de bronconeumologia, 2017

View PDFchevron_right

Management of EGFR-mutated non-small-cell lung cancer: practical implications from a clinical and pathology perspective

Mini Pakkal

Current Oncology

View PDFchevron_right

Clinical features and treatment outcome of non-small cell lung cancer (NSCLC) patients with uncommon or complex epidermal growth factor receptor (EGFR) mutations

Massimo Rugge

Oncotarget, 2017

View PDFchevron_right

Management of EGFR mutated nonsmall cell lung carcinoma patients

Bogdan D. Grigoriu

The European respiratory journal, 2015

View PDFchevron_right

Immediate Versus Delayed Treatment with EGFR Tyrosine Kinase Inhibitors after First-line Therapy in Advanced Non-small-cell Lung CANCER

Ping Li

Chinese journal of cancer research = Chung-kuo yen cheng yen chiu, 2011

View PDFchevron_right

A Phase II Study of Gefitinib With Concurrent Thoracic Radiotherapy in Patients With Unresectable, Stage III Non–small-cell Lung Cancer Harboring EGFR Mutations (WJOG6911L)

Hiroaki Akamatsu

Clinical Lung Cancer, 2019

View PDFchevron_right

Case report: Management of Progressive Lung Cancer Patients after First-Line EGFR Tyrosine Kinase Inhibitor Therapy

Sahrun Sahrun

Folia Medica Indonesiana, 2019

View PDFchevron_right

The Evolving Role of Maintenance Therapy Using Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors (EGFR TKIs) in the Management of Advanced Non-Small-Cell Lung Cancer

Chao Huang

Clinical Medicine Insights. Oncology, 2012

View PDFchevron_right

Multidisciplinary and real life data: practical management of epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer (NSCLC)

Francesco Martella

Journal of Thoracic Disease

View PDFchevron_right

Epidermal Growth Factor Receptor Inhibition in Mutation-Positive Non-Small-Cell Lung Cancer: Is Afatinib Better or Simply Newer?

Hak Choy, Robert Pirker, Luis Paz-ares

Journal of Clinical Oncology, 2013

View PDFchevron_right

Survival Rate Comparison of Non Small Cell Lung Carcinoma Patients Who Are Given by Epidermal Growth Factor Receptor-Tyrosin Kinase Inhibitor and Those Given by First-Line Chemotherapy Treatment

Hasan Nyambe

Nusantara Medical Science Journal, 2022

View PDFchevron_right

EGFR_Mutation_and_Tyrosine_Kinase_Inhibitors_(TKI)_in_Non Small_Cell_Lung_Cancer_An_Overview.pdf

SSR Institute of International Journal of Life Sciences

View PDFchevron_right

Epidermal growth factor receptor (EGFR)—tyrosine kinase inhibitors as a first-line treatment for postoperative recurrent and EGFR-mutated non-small-cell lung cancer

Yojiro Yutaka

Interactive Cardiovascular and Thoracic Surgery, 2021

View PDFchevron_right

Clinicopathologic features of non-small cell lung cancer in India and correlation with epidermal growth factor receptor mutational status

Grace Rebekah

Indian journal of cancer

View PDFchevron_right

Survival Rate in Lung Adenocarcinoma with Mutation of the EGFR Gene with Tyrosine Kinase Inhibitor Treatment

noni soeroso

Open Access Macedonian Journal of Medical Sciences

View PDFchevron_right

Comparison of the effectiveness of erlotinib, gefitinib, and afatinib for treatment of non‑small cell lung cancer in patients with common and rare EGFR gene mutations

Katarzyna Reszka

Oncology Letters, 2017

View PDFchevron_right

The role of the epidermal growth factor receptor tyrosine kinase inhibitors as therapy for advanced, metastatic, and recurrent non-small-cell lung cancer: a Canadian national consensus statement

Barbara Melosky, Flora Krasnoshtein

Current oncology (Toronto, Ont.), 2009

View PDFchevron_right

Epidermal Growth Factor Receptor Mutation Status in the Treatment of Non-small Cell Lung Cancer: Lessons Learned

Mauro Orlando

Cancer Research and Treatment, 2015

View PDFchevron_right

The impact of common and rare EGFR mutations in response to EGFR tyrosine kinase inhibitors and platinum-based chemotherapy in patients with non-small cell lung cancer

Luis Corrales

Lung cancer (Amsterdam, Netherlands), 2015

View PDFchevron_right

Patterns of Progression and Feasibility of Re-biopsy After First-line Erlotinib for Advanced EGFR Mutation-positive Non-small-cell Lung Cancer

José Trigo

Anticancer Research, 2019

View PDFchevron_right

Comparison of Treatment Outcome in EGFR Positive and Negative Patients with Non Small Cell Lung Cancer: A Longitudinal Study

Zuber Ahmad

JOURNAL OF CLINICAL AND DIAGNOSTIC RESEARCH

View PDFchevron_right

Evaluation of Patients with Lung Cancer Treated with Epidermal Growth Factor Receptor–Tyrosine Kinase Inhibitor

Farah Fatmawati

Asian Journal of Oncology, 2018

View PDFchevron_right

Antitumoral Activity of Tyrosine Kinase Inhibitors in Patients with Non-small Cell Lung Cancer Harbouring Rare Epidermal Growth Factor Receptor Mutations

Emmanuel De Laere, Elke Boone

Molecular Diagnosis & Therapy, 2015

View PDFchevron_right

Predicting Clinical Benefit in Non-Small-Cell Lung Cancer Patients Treated with Epidermal Growth Factor Tyrosine Kinase Inhibitors

Lukas Amler

Cold Spring Harbor Symposia on Quantitative Biology, 2005

View PDFchevron_right

First-Line Gefitinib in Patients With Advanced Non-Small-Cell Lung Cancer Harboring Somatic EGFR Mutations

Thomas Lynch

Journal of Clinical Oncology, 2008

View PDFchevron_right

EGFR Mutation Positive Stage IV Non-Small-Cell Lung Cancer: Treatment Beyond Progression (original) (raw)

Related papers